- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.02. | Gilead acquires CAR-T specialist Arcellx for $7.8bn | ||
| 23.02. | EU pledges €225m to develop next generation of flu vaccines | ||
| 23.02. | Novo Nordisk flags board members for re-election amid restructuring efforts | ||
| 23.02. | AstraZeneca's Calquence plus venetoclax gains approval in US to treat CLL | ||
| 23.02. | Roche receives FDA acceptance for giredestrant combo NDA | ||
| 20.02. | Ex-Trump official-ran Altesa secures $75m in Series B funding round | ||
| 20.02. | WHO wants improved universal vaccines to win global influenza battle | ||
| 20.02. | Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research | ||
| 20.02. | Syngene and VivaMed collaborate on therapeutic programmes | ||
| 19.02. | Valneva's Lyme disease vaccine offers beacon of hope amid 2025 sales dip | ||
| 19.02. | J&J to build $1bn US CGT manufacturing site in Pennsylvania | ||
| 19.02. | Novartis enters licensing agreement with UNP for peptide therapeutics | ||
| 19.02. | MSD and Mayo Clinic team up to advance AI in drug development | ||
| 18.02. | FDA to review Moderna's flu jab on agency pivot | ||
| 18.02. | Novo expands injectable Wegovy offering with European higher dose approval | ||
| 18.02. | Evogene and QUT partner on AI-based cancer therapies | ||
| 18.02. | The China factor: US pharma group campaigns for increased competitiveness | ||
| 18.02. | J&J's Rybrevant Faspro gains FDA approval for new dosing in NSCLC | ||
| 17.02. | Pricing and reimbursement delays continue to impact biopharma revenue streams | ||
| 17.02. | Pharma companies venture further afield in search of R&D | ||
| 17.02. | Teijin and Aska Pharmaceutical to co-develop gynaecological drugs | ||
| 17.02. | ExCellThera secures German NUB Status 1 listing for Zemcelpro | ||
| 16.02. | Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages | ||
| 16.02. | PTC pulls Translarna NDA after unfavourable FDA feedback | ||
| 16.02. | FDA issues complete response letter to Disc Medicine's bitopertin NDA |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.